Abstract
No public abstract is available from the verified source records.
Yaoguang Huang, Shuoqi Huang
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Improved survival with ipilimumab in patients with metastatic melanoma
10.1056/nejmoa1003466 · 2010
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
10.1056/nejmoa1200690 · 2012
Cancer immunotherapy using checkpoint blockade
10.1126/science.aar4060 · 2018
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
10.1038/s41571-019-0175-7 · 2019
Understanding the tumor immune microenvironment (TIME) for effective therapy
10.1038/s41591-018-0014-x · 2018
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
10.1038/nm1093 · 2004
Regulatory T cells and immune tolerance
10.1016/j.cell.2008.05.009 · 2008
How regulatory T cells work
10.1038/nri2343 · 2008
Regulatory T cells in cancer immunotherapy
10.1038/cr.2016.151 · 2017
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
10.1016/j.ccell.2023.02.014 · 2023
Helios, a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin
10.1101/gad.12.6.782 · 1998
Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells
10.4049/jimmunol.0904028 · 2010
Helios expression is a marker of T cell activation and proliferation
10.1371/journal.pone.0024226 · 2011
Helios+ and Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans
10.4049/jimmunol.1201379 · 2013
Stable inhibitory activity of regulatory T cells requires the transcription factor Helios
10.1126/science.aad0616 · 2015
Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity
10.1073/pnas.1604765113 · 2016
Acute pharmacological degradation of Helios destabilizes regulatory T cells
10.1038/s41589-021-00802-w · 2021
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy
10.1016/j.chembiol.2023.02.005 · 2023
Identification of germline monoallelic mutations in IKZF2 in patients with immune dysregulation
10.1182/bloodadvances.2021006367 · 2022
Dominant negative variants in IKZF2 cause ICHAD syndrome, a new disorder characterised by immunodysregulation, craniofacial anomalies, hearing impairment, athelia and developmental delay
10.1136/jmg-2022-109127 · 2023
A germline heterozygous dominant negative IKZF2 variant causing syndromic primary immune regulatory disorder and ICHAD
10.1007/s10875-025-01882-2 · 2025
Targeted protein degradation: expanding the toolbox
10.1038/s41573-019-0047-y · 2019
PROTAC targeted protein degraders: the past is prologue
10.1038/s41573-021-00371-6 · 2022
Identification of a primary target of thalidomide teratogenicity
10.1126/science.1177319 · 2010
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs
10.1038/nsmb.2874 · 2014
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells
10.1126/science.1244851 · 2014
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
10.1126/science.aat0572 · 2018
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
10.1038/nature14610 · 2015
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
10.1038/s41589-018-0129-x · 2018
Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy
10.1038/s41467-025-58431-z · 2025
Design and development of IKZF2 and CK1α dual degraders
10.1021/acs.jmedchem.3c01736 · 2023
AlphaFold Protein Structure Database in 2024: providing structure coverage for over 214 million protein sequences
10.1093/nar/gkad1011 · 2024
10.1038/s41587-026-03237-7
10.1038/s41587-026-03237-7
Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide
10.1038/nature13527 · 2014
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins
10.1126/science.1244917 · 2014
Rational discovery of molecular glue degraders via scalable chemical profiling
10.1038/s41589-020-0594-x · 2020
HELIOS-expressing human CD8 T cells exhibit limited effector functions
10.3389/fimmu.2023.1308539 · 2023
The transcription factor Helios restrains the anti-tumor capacity of CD8+ T cells
10.1016/j.celrep.2025.116680 · 2025
Helios is a key transcriptional regulator of outer hair cell maturation
10.1038/s41586-018-0728-4 · 2018
Loss-of-function mutation in IKZF2 leads to immunodeficiency with dysregulated germinal center reactions and reduction of MAIT cells
10.1126/sciimmunol.abe3454 · 2021
Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells
10.1172/jci153514 · doi-reference
Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs
10.1073/pnas.1814446115 · doi-reference
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
10.1182/blood-2018-05-852798 · doi-reference
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
10.1182/blood.2020007081 · doi-reference
Leveraging structural and computational biology for molecular glue discovery
10.1021/acs.jmedchem.5c00076 · doi-reference
Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1
10.1073/pnas.2418985122 · doi-reference
IKZF2 Degradation: it's time to take into account it when designing Cereblon-based PROTACs
10.1002/cbic.202400365 · doi-reference
Discovery of novel potent triple IKZF1/2/3 degraders for the treatment of hematological cancers
10.1021/acs.jmedchem.5c01086 · doi-reference
Discovery of highly potent and selective IKZF2 degraders for cancer immunotherapy
10.1021/acs.jmedchem.6c00500 · doi-reference
The discovery of BMS-986449, a highly potent and selective degrader of the transcription factors Helios (IKZF2) and Eos (IKZF4) for the treatment of solid tumors
10.1158/1538-7445.am2025-nd05 · doi-reference
Overcoming CK1α liability in the discovery of a series of isoIndolinone Glutarimides as selective IKZF2 molecular glue degraders
10.1016/j.bmcl.2025.130263 · doi-reference
Phase 1 DKY709A12101C study in patients with advanced solid tumors treated with DKY709, an IKZF2 degrader, alone or in combination with PDR001, a PD-1 inhibitor
10.1158/1538-7445.am2026-ct006 · doi-reference
Discovery of a novel series of iso-indolinone-based glutarimides as highly efficacious and selective IKZF2 molecular glue degraders
10.1021/acs.jmedchem.5c00668 · doi-reference
Redirecting the neo-substrate specificity of cereblon-targeting PROTACs to Helios
10.1021/acschembio.2c00439 · doi-reference
Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
10.1038/nature16979 · doi-reference
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
10.1038/nature18611 · doi-reference
Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR
10.1038/s41590-018-0051-0 · doi-reference
Interferon-γ drives Treg fragility to promote anti-tumor immunity
10.1016/j.cell.2017.05.005 · doi-reference
Comparative transcriptome analysis reveals distinct genetic modules associated with Helios expression in intratumoral regulatory T cells
10.1073/pnas.1720447115 · doi-reference
Helios is a marker, not a driver, of human Treg stability
10.1002/eji.202149318 · doi-reference
Helios controls a limited subset of regulatory T cell functions
10.4049/jimmunol.1501704 · doi-reference
Helios induces epigenetic silencing of Il2 gene expression in regulatory T cells
10.4049/jimmunol.1200792 · doi-reference
Suppression of Aiolos and Ikaros expression by lenalidomide reduces human ILC3-ILC1/NK cell transdifferentiation
10.1002/eji.201848075 · doi-reference
Helios represses megakaryocyte priming in hematopoietic stem and progenitor cells
10.1084/jem.20202317 · doi-reference